{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T12:31:10Z","timestamp":1744288270122,"version":"3.37.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100009530","name":"Jawaharlal Institute Of Postgraduate Medical Education and Research","doi-asserted-by":"publisher","award":["JIP\/Res\/Intra-PhD\/01\/2014"],"award-info":[{"award-number":["JIP\/Res\/Intra-PhD\/01\/2014"]}],"id":[{"id":"10.13039\/501100009530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.psychres.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,3]],"date-time":"2016-04-03T16:13:30Z","timestamp":1459700010000},"page":"209-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia"],"prefix":"10.1016","volume":"240","author":[{"given":"Alladi","family":"Charan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak Gopal","family":"Shewade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi Philip","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adithan","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2016.04.001_bib1","doi-asserted-by":"crossref","DOI":"10.4088\/PCC.11l01155","article-title":"Prolactin - A biomarker for antipsychotic treatment response?","author":"Agarwal","year":"2011","journal-title":"Prim. Care Companion CNS Disord."},{"key":"10.1016\/j.psychres.2016.04.001_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.schres.2006.02.008","article-title":"Correlation between testosterone, gonadotropins and prolactin and severity of negative symptoms in male patients with chronic schizophrenia","volume":"84","author":"Akhondzadeh","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2016.04.001_bib3","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","article-title":"Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response","volume":"156","author":"Breier","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1043-6618(03)00174-9","article-title":"Risperidone-associated hyperprolactinemia: evaluation in twenty psychiatric outpatients","volume":"48","author":"Brunelleschi","year":"2003","journal-title":"Pharmacol. Res."},{"issue":"Suppl","key":"10.1016\/j.psychres.2016.04.001_bib5","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0920-9964(98)00159-5","article-title":"Neuroleptic-induced hyperprolactinemia","volume":"35","author":"Dickson","year":"1999","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2016.04.001_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/0269216307087148","article-title":"Prolactin and dopamine: what is the connection? A review article","volume":"22","author":"Fitzgerald","year":"2008","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.psychres.2016.04.001_bib300","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl 2","key":"10.1016\/j.psychres.2016.04.001_bib8","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/S0306-4530(02)00128-2","article-title":"Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials","volume":"28","author":"Kinon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.psychres.2016.04.001_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.euroneuro.2008.07.010","article-title":"Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole","volume":"18","author":"Kwon","year":"2008","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.pnpbp.2005.11.037","article-title":"The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients","volume":"30","author":"Lee","year":"2006","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib11","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1994.03950100009002","article-title":"Effects of the menstrual cycle on dependent variables in mood disorder research","volume":"51","author":"Leibenluft","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl B","key":"10.1016\/j.psychres.2016.04.001_bib12","first-page":"S126","article-title":"Predictors of response to clozapine","volume":"55","author":"Lieberman","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib13","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e31822cfff2","article-title":"DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers","volume":"31","author":"L\u00f3pez-Rodr\u00edguez","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/YIC.0000000000000063","article-title":"Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents","volume":"30","author":"Margari","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01244450","article-title":"Prolactin responses to haloperidol in drug-free and treated schizophrenic patients","volume":"83","author":"Markianos","year":"1991","journal-title":"J. Neural Transm. Gen. Sect."},{"key":"10.1016\/j.psychres.2016.04.001_bib301","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2174\/157488711793980138","article-title":"Recent clinical aspects of hyperprolactinemia induced by antipsychotics","volume":"6","author":"Milano","year":"2011","journal-title":"Rev. Recent Clin. Trials"},{"key":"10.1016\/j.psychres.2016.04.001_bib16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0165-1781(92)90001-J","article-title":"Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements during maintenance haloperidol treatment in male patients with schizophrenia","volume":"41","author":"Newcomer","year":"1992","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2016.04.001_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004850-199400940-00008","article-title":"Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients","volume":"9","author":"Otani","year":"1994","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib18","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/JCP.0b013e318272688b","article-title":"Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis","volume":"32","author":"P\u00e9rez-Iglesias","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.psychres.2012.05.010","article-title":"Prolactin and thyroid hormone levels are associated with suicide attempts in psychiatric patients","volume":"200","author":"Pompili","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2016.04.001_bib20","first-page":"924","article-title":"Atypical antipsychotics in the treatment of schizophrenia","volume":"322","author":"Prior","year":"2001","journal-title":"Br. Med. J."},{"key":"10.1016\/j.psychres.2016.04.001_bib21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1023\/A:1021648128758","article-title":"Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics","volume":"28","author":"Ritchie","year":"2003","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.psychres.2016.04.001_bib22","first-page":"7","article-title":"Prolactin secretion in healthy adults is determined by gender age body mass index","author":"Roelfsema","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2016.04.001_bib23","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/FPC.0b013e3283647c33","article-title":"The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys","volume":"23","author":"Roke","year":"2013","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.psychres.2016.04.001_bib24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pnpbp.2013.05.010","article-title":"Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data","volume":"45","author":"Tsuboi","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib25","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S1734-1140(12)70848-4","article-title":"Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients","volume":"64","author":"Tybura","year":"2012","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.psychres.2016.04.001_bib26","first-page":"357","article-title":"Serum prolactin as a correlate of clinical response to haloperidol","volume":"11","author":"Van Putten","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2016.04.001_bib27","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib28","first-page":"1483","article-title":"Gender differences in the temporal organization of proclactin (PRL) secretion: evidence for a sleep-independent circadian rhythm of circulating PRL levels- a clinical research center study","volume":"81","author":"Waldstreicher","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.psychres.2016.04.001_bib29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0269881107077357","article-title":"Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia","volume":"21","author":"Wang","year":"2007","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.psychres.2016.04.001_bib30","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.pnpbp.2008.05.006","article-title":"Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients","volume":"32","author":"Yasui-Furukori","year":"2008","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1192\/bjp.185.2.147","article-title":"Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele","volume":"185","author":"Young","year":"2004","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.psychres.2016.04.001_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00213-004-1975-7","article-title":"Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study","volume":"178","author":"Zhang","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.psychres.2016.04.001_bib33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0165-1781(02)00022-7","article-title":"Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia","volume":"109","author":"Zhang","year":"2002","journal-title":"Psychiatry Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116301615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116301615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T13:05:09Z","timestamp":1692277509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178116301615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":35,"alternative-id":["S0165178116301615"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2016.04.001","relation":{},"ISSN":["0165-1781"],"issn-type":[{"type":"print","value":"0165-1781"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}